Newsroom
Sorted by: Latest
-
L’Initiative Moyen-Orient Vert annonce sa participation à la COP17 pour renforcer la coopération régionale contre la désertification
Riyad, Arabie saoudite--(BUSINESS WIRE)--Middle East Green Initiative Announces Participation in UNCCD COP17...
-
Middle East Green Initiative Announces Participation in UNCCD COP17 to Bolster Regional Cooperation in Combating Desertification and Restoring Degraded Land
RIYADH, Saudi Arabia--(BUSINESS WIRE)--Middle East Green Initiative Announces Participation in UNCCD COP17...
-
Pilot Fiber Completes Acquisition of Extenet Systems' Enterprise Fiber Business
NEW YORK--(BUSINESS WIRE)--Pilot Fiber, an enterprise connectivity provider in the New York metro area, announced today it has completed its acquisition of the enterprise fiber business of Extenet Systems, LLC, effective August 15, 2026. The acquired network, including the former Hudson Fiber Network and Axiom Fiber Network assets, now operates under Pilot’s ownership. The completed transaction extends Pilot's owned fiber network into New Jersey and adds more than 20 data centers to its footpri...
-
Exchange Income Corporation Announces August 2026 Dividend at Recently Increased Rate
WINNIPEG, Manitoba--(BUSINESS WIRE)--Exchange Income Corporation Announces August 2026 Dividend at Recently Increased Rate...
-
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpr...
-
Dynatrace Announces Proposed Private Placement of $1.25 Billion of Exchangeable Senior Notes
BOSTON--(BUSINESS WIRE)--Dynatrace, Inc. (“Dynatrace”) (NYSE: DT), the leading AI-powered observability platform, today announced that its indirect wholly-owned subsidiary, Dynatrace LLC (the “Issuer”), intends to offer, subject to market conditions and other factors, $1.25 billion aggregate principal amount of its Exchangeable Senior Notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A und...
-
D-Wave Appoints Kevan P. Krysler to Board of Directors and Audit Committee
PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS) ("D-Wave" or the "Company"), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced the appointment of veteran technology finance executive Kevan P. Krysler to its Board of Directors and Audit Committee. Krysler currently serves as chief financial officer of Carbon Robotics, a privately held company specializing in physical AI and robotics for...
-
Great Hill Partners Appoints Sam Liu as Director of AI
BOSTON--(BUSINESS WIRE)--Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies, today announced that Sam Liu has joined the firm’s Growth Team as Director of AI, reflecting Great Hill’s continued focus on applying AI across the full scope of its investment and value creation activities. In this role, Liu will partner with Great Hill’s investment professionals to further develop the firm’s AI capabilities, combining technology and repeatable processes to st...
-
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients. “The rapid pace of enrollment underscores both the significant unmet need for new treatment options in PPF and the strong interest in nebulized Tyvas...
-
First Bellwether Trial Today Against Reckitt Benckiser’s Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--Reckitt Benckiser (LON: RKT) subsidiary, Mead Johnson is facing the first bellwether today as part of a multidistrict litigation (MDL) in the US District Court for the Northern District of Illinois over its infant formula Enfamil being linked to necrotizing enterocolitis (NEC) in a premature infant. Inman v. Mead Johnson & Company, LLC, et al. is the first case against Mead Johnson in the MDL to proceed to trial. NEC is a severe intestinal disease that can...